TSPAN1 and neoplasm: In addition, increased TSPAN1 immunoreactivity correlated with poor overall survival (Log-rank = 7.272, p = 0.007, Figure 4D), poor tumor differentiation (Spearman r = 0.184, p = 0.026) and high TNM stage (Spearman r = 0.170, p = 0.040).